- Home
- SPRO vs THTX Comparison
SPRO vs THTX Comparison
Compare SPRO & THTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- THTX
- Stock Information
- Founded
- SPRO 2013
- THTX 1993
- Country
- SPRO United States
- THTX Canada
- Employees
- SPRO N/A
- THTX N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- THTX Biotechnology: Pharmaceutical Preparations
- Sector
- SPRO Health Care
- THTX Health Care
- Exchange
- SPRO Nasdaq
- THTX Nasdaq
- Market Cap
- SPRO 121.0M
- THTX 144.8M
- IPO Year
- SPRO 2017
- THTX N/A
- Fundamental
- Price
- SPRO $1.90
- THTX $3.31
- Analyst Decision
- SPRO Buy
- THTX Hold
- Analyst Count
- SPRO 4
- THTX 1
- Target Price
- SPRO $5.00
- THTX N/A
- AVG Volume (30 Days)
- SPRO 323.5K
- THTX 416.1K
- Earning Date
- SPRO 11-13-2025
- THTX 10-09-2025
- Dividend Yield
- SPRO N/A
- THTX N/A
- EPS Growth
- SPRO N/A
- THTX N/A
- EPS
- SPRO N/A
- THTX N/A
- Revenue
- SPRO $48,576,000.00
- THTX $84,378,000.00
- Revenue This Year
- SPRO N/A
- THTX N/A
- Revenue Next Year
- SPRO N/A
- THTX $13.76
- P/E Ratio
- SPRO N/A
- THTX N/A
- Revenue Growth
- SPRO N/A
- THTX 2.19
- 52 Week Low
- SPRO $0.51
- THTX $1.12
- 52 Week High
- SPRO $3.22
- THTX $3.34
- Technical
- Relative Strength Index (RSI)
- SPRO 40.19
- THTX 74.01
- Support Level
- SPRO $1.91
- THTX $3.26
- Resistance Level
- SPRO $2.18
- THTX $3.31
- Average True Range (ATR)
- SPRO 0.09
- THTX 0.02
- MACD
- SPRO 0.00
- THTX -0.00
- Stochastic Oscillator
- SPRO 11.94
- THTX 73.68
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About THTX Theratechnologies Inc.
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.